Table 4.
Characteristics of patients treated with MRgFUS, UAE and Myomectomy
|
Patient characteristics |
MRgFUS |
UAE |
Myomectomy |
P-Value
a
|
|---|---|---|---|---|
| (N = 14) | (N = 4,092) | (N = 10,320) | ||
|
Age |
|
|
|
|
| 25-34 |
0.0% |
4.0% |
33.1% |
|
| 35-44 |
28.6% |
46.4% |
55.3% |
|
| 45-54 |
71.4% |
49.7% |
11.6% |
0.000 |
|
Region |
|
|
|
|
| Northeast |
NR |
13.8% |
14.2% |
|
| Midwest |
NR |
18.8% |
15.0% |
|
| South |
NR |
52.4% |
54.5% |
|
| West |
NR |
14.2% |
15.7% |
|
| Unknown |
NR |
0.7% |
0.6% |
0.000 |
|
Employment details |
|
|
|
|
| Employee (not spouse or dependent) |
64.3% |
71.7% |
77.5% |
0.000 |
|
Plan type |
|
|
|
|
| Fee for service |
7.1% |
3.9% |
3.0% |
|
| HMO |
28.6% |
29.3% |
24.4% |
|
| Point of Service (POS) |
7.1% |
13.0% |
15.0% |
|
| Preferred Provider Organization |
57.1% |
47.9% |
51.7% |
|
| Capitated POS |
0.0% |
2.4% |
2.0% |
|
| Consumer Driven Health Plan (CDHP) |
0.0% |
2.1% |
2.6% |
0.000 |
|
Year of index date |
|
|
|
|
| 2004 |
0.0% |
7.4% |
10.8% |
|
| 2005 |
7.1% |
13.8% |
13.4% |
|
| 2006 |
14.3% |
15.2% |
14.4% |
|
| 2007 |
28.6% |
16.5% |
17.1% |
|
| 2008 |
21.4% |
19.0% |
19.5% |
|
| 2009 |
21.4% |
27.4% |
24.2% |
0.000 |
|
Sociodemographics of ZIP Code of residence |
|
|
|
|
| Median household income |
|
|
|
|
| Quintile 1 ($0,$28,280) |
0.0% |
8.3% |
9.2% |
|
| Quintile 2 ($28,281, $33,680) |
7.1% |
8.3% |
9.5% |
|
| Quintile 3 ($33,681, $39,204) |
14.3% |
16.4% |
16.5% |
|
| Quintile 4 ($39,205, $48,749) |
35.7% |
19.2% |
21.1% |
|
| Quintile 5 (≥$48,750) |
42.9% |
47.8% |
43.7% |
0.001 |
| % over 25 with college degree |
|
|
|
|
| Quintile 1 (0-7%) |
0.0% |
0.2% |
0.3% |
|
| Quintile 2 (8-11%) |
0.0% |
2.3% |
2.6% |
|
| Quintile 3 (12-15%) |
14.3% |
13.5% |
13.2% |
|
| Quintile 4 (16-24%) |
71.4% |
29.7% |
31.0% |
|
| Quintile 5 (≥25%) |
14.3% |
54.2% |
52.9% |
0.333 |
| % Black |
|
|
|
|
| Quintile 1 (0%) |
0.0% |
3.7% |
3.5% |
|
| Quintile 2 (0.1-0.3%) |
0.0% |
7.3% |
7.8% |
|
| Quintile 3 (0.4-1.3%) |
28.6% |
15.5% |
15.6% |
|
| Quintile 4 (1.4-8.5%) |
14.3% |
22.2% |
23.6% |
|
| Quintile 5 (≥8.6%) |
57.1% |
51.2% |
49.5% |
0.050 |
|
Surgical setting |
|
|
|
|
| Inpatient |
0.0% |
18.3% |
74.6% |
|
| Outpatient |
100.0% |
81.7% |
25.4% |
0.000 |
|
Use of pharmacotherapy during baseline |
|
|
|
|
| NSAIDs (non-steroidal anti-inflammatories) |
35.7% |
27.9% |
24.9% |
0.001 |
| Hormone therapy |
42.9% |
31.1% |
40.5% |
0.000 |
|
Healthcare use during baseline |
|
|
|
|
| Any inpatient visits |
14.3% |
5.7% |
7.0% |
0.010 |
| Any ER visits |
50.0% |
20.8% |
24.4% |
0.000 |
|
Baseline health status |
|
|
|
|
| Avg. Charlson Cormorbidity Index |
0.14 |
0.23 |
0.17 |
|
| Charlson Cormorbidity Index >0 |
14.3% |
16.0% |
12.8% |
0.000 |
| Avg. Number of Psychiatric Diagnostic Groupings |
2.57 |
2.06 |
2.81 |
|
| Number of Psychiatric Diagnostic Groupings >1 |
50.0% |
58.5% |
76.4% |
0.000 |
| Menstrual disorders |
64.3% |
56.3% |
45.9% |
0.000 |
| Pelvic pain |
42.9% |
24.0% |
31.3% |
0.000 |
| Anemias |
7.1% |
28.4% |
17.9% |
0.000 |
| Inflammatory disease |
28.6% |
14.2% |
18.4% |
0.000 |
| Noninflammatory disease |
7.1% |
14.0% |
17.6% |
0.000 |
| Endometriosis |
0.0% |
2.2% |
5.2% |
0.000 |
| Pregnancy |
7.1% |
2.9% |
15.2% |
0.000 |
| Urinary problems |
0.0% |
3.4% |
3.7% |
0.508 |
| Constipation or gas |
7.1% |
2.8% |
2.9% |
0.605 |
| Other disorders of the uterus |
14.3% |
19.4% |
13.3% |
0.000 |
| Genital prolapse |
0.0% |
0.5% |
0.6% |
0.745 |
| Benign neoplasm of the uterus |
0.0% |
0.1% |
0.5% |
0.003 |
| Infertility |
0.0% |
1.0% |
14.8% |
0.000 |
| Breast cancer |
0.0% |
0.6% |
0.5% |
0.729 |
| a. P-value from chi-square test of significance of difference between the groups |
|
|||
| NR = not reportable due to small sample size | ||||